Diagnostic challenges in diabetic retinopathy: IJO Case Report

Written By :  Dr Ishan Kataria
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-12-28 03:30 GMT   |   Update On 2021-12-28 03:30 GMT
Advertisement

A 67-year-old male of Middle-Eastern ethnicity presented with complaints of defective vision in both eyes for the past 1 year. Examination revealed a best‑corrected visual acuity of 20/100 in the right eye (OD) and 20/70 in the left eye (OS). The patient was diagnosed with type 2 diabetes mellitus more than 10 years ago and had high glycated hemoglobin (HB1AC: 10.2%). The patient was seen elsewhere and diagnosed with moderate nonproliferative diabetic retinopathy (NPDR) with perifoveal exudation in both eyes. The patient had renal failure and is on dialysis three times a week, making him an unsuitable candidate for fluorescein angiography. Fundus examination revealed a hypopigmented area in the macula of OD.

Advertisement

What is the next step?

Additional imaging, including optical coherence tomography (OCT) and OCT angiography (OCTA).

Findings:

(a). There was significant intraretinal fluid and a temporal parafoveal hyperreflective lesion in the outer retina. There was mild atrophy of the outer retinal layers in this region. The OCT angiography (OCTA) superficial capillary plexus (SCP) showed a right‑angled venule (yellow arrow) and flow void areas in the perifoveal region

(b). The deep capillary plexus (DCP) also showed the right-angled venule with telangiectatic vessels in the perifoveal region

(c). The outer retina to choriocapillaris (ORCC) slab showed distinct subretinal neovascularization.

(e) OCT of the right eye one month after aflibercept injection showed a reduction in the intraretinal fluid and a decrease in the outer retinal hyper-reflectivity. There was mild atrophy of the retinal layers suggestive of macular telangiectasia.

Diagnosis: The diagnosis was moderate NPDR with type 2 macular telangiectasia (MacTel) stage 5 in OD. Management The patient was advised therapy with intravitreal injections of anti‑VEGF (aflibercept 2 mg/0.1 ml) for the subretinal neovascularization and intraretinal fluid. The patient experienced subjective improvement of vision (improved to 20/70 from 20/100 in OD). There was decrease in the intraretinal fluid at 1 month after the injection.

MacTel is characterized by telangiectatic retinal vessels with retinal thinning, atrophy of the Muller cells, and progressive photoreceptor damage. The pathological changes in MacTel begin juxtafoveally and can be complicated by the development of subretinal neovascularization, leading to severely decreased vision. There is an overall higher incidence of type 2 MacTel in patients with diabetes mellitus. In addition, certain histopathological changes are common between the two entities.The occurrence of subretinal neovascularization in MacTel along with NPDR is very rare (less than 3% cases). Therefore, these patients require meticulous retinal imaging when subretinal neovascularization is suspected. This case by Aniruddha Agarwal highlights the importance of OCT and OCTA in establishing the accurate diagnosis and initiating therapy in the patient.

Source: Agarwal A. Co-existing retinal pathologies: Diagnostic challenges in diabetic retinopathy. Indian J Ophthalmol 2021;69:2931.

Tags:    
Article Source : Indian J Ophthalmology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News